New Single-Use Pall® XRS 20 Bioreactor System Enhances Cell Culture Performance in Biotechnology Applications

Fri Mar 22, 2013 3:19pm EDT

* Reuters is not responsible for the content in this press release.

Next-Generation `Rocker` Bioreactor is Ideal for Suspension Cultures for Life
Sciences Applications Up to Full GMP Production
PORT WASHINGTON, N.Y.--(Business Wire)--
Pall Corporation (NYSE:PLL), a global leader in filtration, separation and
purification, today introduced the XRS 20 Bioreactor System, a new bioreactor
with unique agitation properties that incorporates a single-use, easy-to-use
Allegro 3D biocontainer. This next generation `rocker` bioreactor, designed for
cultivation of mammalian cells in suspension culture, is equally suitable for
applications ranging from general life sciences research to seed train
operations and full Good Manufacturing Practice (GMP) production at the 2-to-20
liter scale.
The Pall XRS 20 Bioreactor System's unique bi-axial agitation properties improve
cell culture performance. (Photo: Business Wire)

The XRS 20 System`s unique bi-axial agitation promotes better mixing and higher
mass transfer, which expedites transport of nutrients and metabolites in the
cellular micro-environment. This allows cultures to reach higher densities with
overall greater viabilities, leading to significantly higher protein expression

To ensure operational simplicity, the system includes the following features:

* Allegro XRS 20 biocontainer with integrated components (sensors, filters,
drain and tubing sets) for rapid installation and efficient harvesting 
* Advanced XRS 20 controller with touchscreen interface for easy monitoring and
control of process parameters

A fully enclosed XRS 20 platform with interlock provides operator safety while
protecting sensitive media components from light. 

"The versatile, easy-to-use XRS 20 Bioreactor System combines state-of-the-art,
single-use technology with advanced controls and features that improve cell
culture performance," said Ken Frank, President, Pall BioPharmaceuticals. 

To learn more about the XRS 20 Bioreactor System please visit 

Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the
demanding needs of customers discovering, developing and producing biotech
drugs, vaccines and classic pharmaceuticals. The company`s membranes and
membrane devices optimize detection and sample preparation in the drug research,
clinical diagnostics, genomics, and proteomics markets. Pall is a leading
provider of separation systems and single-use filtration and purification
technologies to pharmaceutical and biotechnology companies to support faster
development of new drugs and vaccines that are safer and require less energy and
water to produce. Pall technologies are also used in clinical institutions and
the food and beverage industries. 

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader
providing solutions to meet the critical fluid management needs of customers
across the broad spectrum of life sciences and industry. Pall works with
customers to advance health, safety and environmentally responsible
technologies. The Company`s engineered products enable process and product
innovation and minimize emissions and waste. Pall Corporation is an S&P 500
company serving customers worldwide. Pall has been named a "top green company"
by Newsweek magazine. To see how Pall is helping enable a greener, safer, more
sustainable future, follow us on Twitter @PallCorporation or visit

Photos/Multimedia Gallery Available:

Pall Corporation
Rebecca Kale
Senior Marketing Communications Manager
Telephone: +44 (0)2392 303733

Copyright Business Wire 2013